Ascendis Pharma A/S ((ASND)) has held its Q2 earnings call. Read on for the main highlights of the call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ascendis Pharma A/S recently held its earnings call, showcasing a positive outlook despite some financial challenges. The company reported strong revenue growth, significant regulatory milestones, and promising advancements in their product pipeline. While currency impacts and increased SG&A expenses posed challenges, the overall sentiment was optimistic, with expectations of sustained growth and financial improvements.
Strong YORVIPATH Revenue Growth
YORVIPATH demonstrated impressive revenue growth in Q2 2025, reaching EUR 103 million, more than doubling from the previous quarter despite facing currency headwinds. In the U.S. market alone, over 1,500 prescribers wrote prescriptions for approximately 3,100 unique patients, highlighting the product’s growing acceptance and demand.
Regulatory Approvals and Progress
Ascendis Pharma achieved significant regulatory milestones with the FDA approval of TransCon Growth Hormone for adult growth hormone deficiency. Additionally, TransCon PTH received marketing authorization in the U.S., EU, and UK for treating hypoparathyroidism, marking a major step forward in the company’s regulatory journey.
TransCon CNP Priority Review
The FDA granted priority review for TransCon CNP, recognizing its potential to enhance the treatment of achondroplasia. The PDUFA date is set for November 30, 2025, underscoring the urgency and importance of this development in the company’s pipeline.
Financial Performance
Ascendis Pharma reported total Q2 revenue of EUR 158 million, driven by strong product sales from YORVIPATH and SKYTROFA. The company is on the brink of achieving cash flow positivity, reflecting its robust financial health and strategic growth initiatives.
Currency Headwinds Impacting Revenue
Currency exchange rates negatively impacted Ascendis Pharma’s total product revenue by EUR 7.6 million in Q2 2025. Despite this challenge, the company maintained strong revenue growth, showcasing its resilience in the face of external financial pressures.
Increased SG&A Expenses
SG&A expenses rose to EUR 107.6 million in Q2 2025, up from EUR 74.3 million in the same period last year. This increase was primarily driven by the company’s global commercial expansion efforts, reflecting its commitment to broadening its market reach.
Forward-Looking Guidance
Looking ahead, Ascendis Pharma remains optimistic about its growth trajectory. YORVIPATH’s revenue is expected to continue its upward trend, with commercial agreements in over 75 countries. SKYTROFA’s revenue also shows promising growth, with new patient starts on the rise. The company is progressing towards achieving cash flow positivity on a quarterly basis, supported by a strong cash position of EUR 494 million at the end of the quarter.
In conclusion, Ascendis Pharma’s earnings call painted a picture of a company on the rise, with strong revenue growth, significant regulatory achievements, and promising product developments. Despite facing currency and expense challenges, the overall sentiment was positive, with expectations of continued financial improvements and growth in the coming quarters.